| Active substance |
Capecitabine
|
| Water Retention |
No significant effect
|
| Hepatotoxicity |
Possible, especially in patients with pre-existing liver conditions
|
| Lab Test |
Monitoring of complete blood counts, liver and renal function tests recommended
|
| Also known as |
Xeloda
|
| WAREHOUSE |
International Warehouse 2
|
| Blood pressure |
No significant effect on blood pressure
|
| Trade name |
Xeloda
|
| Storage conditions |
Store at room temperature, protect from moisture and light
|
| Chemical name |
5'-Deoxy-5-fluoro-N-[(pentyloxy)carbonyl]-cytidine
|
| Formula |
C15H22FN3O6
|
| Substance class |
Antimetabolite, Fluoropyrimidine
|
| Main action |
Antineoplastic agent
|
| Half-life |
Approximately 38-45 minutes
|
| Dosage (medical) |
Typically, 1250 mg/mВІ twice daily for 2 weeks followed by a 1-week rest period, administered as 3-week cycles
|
| Dosage (sports) |
Not applicable
|
| Effects |
Effective in halting the progression of certain types of cancers by interfering with DNA production
|
| Side effects |
Diarrhea, hand-foot syndrome, nausea, vomiting, fatigue, dermatitis, neutropenia, anemia
|
| Use in sports |
None
|
| Manufacturer |
Med Ilac
|
There are no reviews yet.